{"id":2935,"date":"2019-02-08T06:30:00","date_gmt":"2019-02-08T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/"},"modified":"2019-02-08T06:30:00","modified_gmt":"2019-02-08T06:30:00","slug":"xvivo-perfusion-ab-publ-bokslutskommunike-2018","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/","title":{"rendered":"XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>STARK TILLV\u00c4XT OCH GOD EBITDA-MARGINAL AVSLUTAR \u00c5RET<\/strong><\/div>\n<p>FJ\u00c4RDE KVARTALET 2018 (OKT \u2013 DEC)<\/p>\n<ul>\n<li><span>Total f\u00f6rs\u00e4ljning under kvartalet \u00f6kade med 40 procent och uppgick till 58,4 MSEK (41,6). \u00d6kningen motsvarar 33 procent i lokala valutor. Segment f\u00f6rs\u00e4ljning utan kapitalvaror* \u00f6kade under kvartalet med 33 procent och uppgick till 52,3 MSEK (39,4). \u00d6kningen motsvarar 26 procent i lokala valutor utan kapitalvaror stod varm perfusion f\u00f6r 50 procent (43). <\/span><\/li>\n<li><span>\u00a0R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 10,5 MSEK (8,6) motsvarande en EBITDA-marginal om 18 procent. F\u00f6r j\u00e4mf\u00f6relsekvartalet 2017 uppgick EBITDA justerat f\u00f6r j\u00e4mf\u00f6relsest\u00f6rande poster till 9,1 MSEK.<\/span><\/li>\n<li><span>\u00a0R\u00f6relseresultatet uppgick till 6,1 MSEK (4,7), efter att avskrivningar om 4,4 MSEK (3,8) belastat kvartalet.<\/span><\/li>\n<li><span>\u00a0Nettoresultatet uppgick till 4,9 MSEK (5,6), vilket gav ett resultat per aktie om 0,19 SEK (0,21).<\/span><\/li>\n<li><span>\u00a0Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten uppgick under kvartalet till -2,4 MSEK (7,9), fr\u00e4mst p\u00e5verkat av \u00f6kade r\u00f6relsefordringar p\u00e5 grund av \u00f6kad f\u00f6rs\u00e4ljning under kvartalet.<\/span><\/li>\n<li><span>\u00a04 XPS\u2122 levererades under kvartalet. <\/span><\/li>\n<\/ul>\n<p><span>PERIODEN 2018 (JAN \u2013 DEC)<\/span><strong><span><br \/> <\/span><\/strong><\/p>\n<ul>\n<li><span>Total f\u00f6rs\u00e4ljning under perioden \u00f6kade med 27 procent och uppgick till 187,9 MSEK (148,3). \u00d6kningen motsvarar 23 procent i lokala valutor. Segment f\u00f6rs\u00e4ljning utan kapitalvaror* \u00f6kade under perioden med 22 procent och uppgick till 172,7 MSEK (141,0). \u00d6kningen motsvarar 19 procent i lokala valutor.\u00a0<\/span><\/li>\n<li><span>\u00a0F\u00f6rs\u00e4ljning av varm perfusion utan kapitalvaror** uppvisade en tillv\u00e4xt om cirka 50 procent f\u00f6r perioden. Av f\u00f6rs\u00e4ljning utan kapitalvaror stod varm perfusion f\u00f6r 43 procent (35). \u00a0<\/span><\/li>\n<li><span>\u00a0R\u00f6relseresultatet f\u00f6re avskrivningar (EBITDA) uppgick till 30,9 MSEK (22,0) motsvarande en EBITDA-marginal om 16 procent. F\u00f6r j\u00e4mf\u00f6relseperioden 2017 uppgick EBITDA justerat f\u00f6r j\u00e4mf\u00f6relsest\u00f6rande poster till 24,8 MSEK. \u00a0<\/span><\/li>\n<li><span>\u00a0R\u00f6relseresultatet uppgick till 14,0 MSEK (7,1), efter att avskrivningar om 16,9 MSEK (14,9) belastat perioden.\u00a0<\/span><\/li>\n<li><span>\u00a0Nettoresultatet uppgick till 12,7 MSEK (6,3), vilket gav ett resultat per aktie om 0,48 SEK (0,25).\u00a0<\/span><\/li>\n<li><span>\u00a0Kassafl\u00f6det fr\u00e5n den l\u00f6pande verksamheten uppgick under perioden till 23,6 MSEK (22,2). \u00a0<\/span><\/li>\n<li><span>\u00a0Nyemission till f\u00f6ljd av utnyttjande av teckningsoptioner gav ett tillskott om cirka 19 MSEK. \u00a0<\/span><\/li>\n<li><span>\u00a0PMA-ans\u00f6kan f\u00f6r STEEN Solution\u2122 och XPS\u2122 har inl\u00e4mnats till FDA.\u00a0<\/span><\/li>\n<li><span>\u00a0Perfadex Plus, en uppgraderad version av Perfadex, har lanserats i Europa och USA.<\/span><\/li>\n<li><span>\u00a0Analys av resultat fr\u00e5n PrimECC<sup>\u00ae<\/sup>-studien visade att produkten \u00e4r s\u00e4ker samt visade p\u00e5 positiva kliniska resultat.<\/span><\/li>\n<li><span>\u00a0United Therapeutics och XVIVO Perfusion har inlett samarbete och United Therapeutics har k\u00f6pt tv\u00e5 XPS\u2122.<\/span><\/li>\n<li><span>\u00a08 XPS\u2122 och LS\u2122 levererades under perioden januari-december 2018. Vid \u00e5rets utg\u00e5ng hade 49 kliniker tillg\u00e5ng till XPS\u2122 eller LS\u2122.<\/span><\/li>\n<\/ul>\n<p>TELEFONKONFERENS<\/p>\n<p><span>VD Magnus Nilsson presenterar rapporten vid en telefonkonferens klockan 14:00 fredagen den 8 februari 2019. Telefon: +46 (0)8 5664 2651, ange kod 61837473#<\/span><\/p>\n<p><span> <em><\/em><\/span><\/p>\n<p><span>G\u00f6teborg den 8 februari 2019<\/span><br \/><span> XVIVO Perfusion AB (publ)<\/span><br \/><span> Magnus Nilsson, VD<\/span><\/p>\n<p><span>*Koncernens r\u00f6relsesegment utg\u00f6rs av f\u00f6rs\u00e4ljning utan kapitalvaror samt f\u00f6rs\u00e4ljning av kapitalvaror<\/span><\/p>\n<p><strong><span>** <\/span><\/strong><span>STEEN Solution\u2122 samt produkter och tj\u00e4nster relaterade till anv\u00e4ndningen av XPS\u2122 och LS\u2122<\/span>\u00a0<\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, +46 735 192159, christoffer.rosenblad@xvivoperfusion.com<br \/>Magnus Nilsson, VD, +46 31-788 21 50, magnus.nilsson@xvivoperfusion.com<\/span><\/p>\n<p><span>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, www.xvivoperfusion.com<\/span><\/p>\n<p><span>Denna information \u00e4r s\u00e5dan information som Xvivo Perfusion AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande klockan 7:30 den 8 februari 2019.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>STARK TILLV\u00c4XT OCH GOD EBITDA-MARGINAL AVSLUTAR \u00c5RET FJ\u00c4RDE KVARTALET 2018 (OKT \u2013 DEC) Total f\u00f6rs\u00e4ljning under kvartalet \u00f6kade med 40&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-2935","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim","mfn-news-tag-mfn-report-interim-q4","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-mar","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-report"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018 - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018 - XVIVO\" \/>\n<meta property=\"og:description\" content=\"STARK TILLV\u00c4XT OCH GOD EBITDA-MARGINAL AVSLUTAR \u00c5RET FJ\u00c4RDE KVARTALET 2018 (OKT \u2013 DEC) Total f\u00f6rs\u00e4ljning under kvartalet \u00f6kade med 40...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\\\/\",\"name\":\"XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018 - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2019-02-08T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018 - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018 - XVIVO","og_description":"STARK TILLV\u00c4XT OCH GOD EBITDA-MARGINAL AVSLUTAR \u00c5RET FJ\u00c4RDE KVARTALET 2018 (OKT \u2013 DEC) Total f\u00f6rs\u00e4ljning under kvartalet \u00f6kade med 40...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/","name":"XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018 - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2019-02-08T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-perfusion-ab-publ-bokslutskommunike-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO Perfusion AB (publ) Bokslutskommunik\u00e9 2018"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/2935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=2935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}